Levodopa-entacapone-carbidopa intestinal gel infusion for Parkinson’s disease: An analysis of data collected from the Swedish national register of Parkinson’s disease.
Objective: To investigate efficacy, tolerability, and safety of levodopa-entacapone-carbidopa intestinal gel (LECIG) in Parkinson’s disease. Background: LECIG was introduced in 2019. The approval was based…Opicapone’s Effects on Progression Scales in Relation to the 9-Symptom Wearing-off Questionnaire: the OPTIPARK Study
Objective: This study aims to evaluate changes in Parkinson’s disease (PD) progression scales in patients with PD and motor fluctuations (MF) treated with once-daily opicapone…Levodopa-Entacapone-Carbidopa Intestinal Gel in advanced Parkinson’s disease: a single center experience
Objective: To evaluate the efficacy of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIG) in achieving adequate control of motor complications in patients with advanced Parkinson’s Disease (APD). Background:…Effect of variants in COMT and UGT1A genes on clinical response in patients with Parkinson’s disease treated with opicapone
Objective: To identify genetic variants associated with different clinical responses in patients with Parkinson’s disease(PD) treated with opicapone. Background: Opicapone is a catechol‐O‐methyltransferase(COMT) inhibitor used…Systematic Review and Network Meta-Analysis of COMT and MAO-B Inhibitors in Parkinson’s Patients with Motor Fluctuations
Objective: This study compared the effects of catechol-O-methyl transferase (COMT) inhibitors and monoamine oxidase‑B (MAO-B) inhibitors on mean change from baseline to end-of-study in OFF-time…OPICAPONE ADD-ON THERAPY IN LEVODOPA-CARBIDOPA INTESTINAL GEL INFUSION: which patient might benefit the most?
Objective: To explore the benefit of Opicapone (OPC) add-on to levodopa-carbidopa intestinal gel (LCIG) in different phenotypes of Parkinson’s Disease (PD) patients. Background: LCIG monotherapy…The effect of co-administration of opicapone on the pharmacokinetics of levodopa
Objective: Few studies have examined levodopa (LD) pharmacokinetics in combination with opicapone (OPC) in Japanese patients with Parkinson's disease (PD). Therefore, we investigated changes in…Opicapone use in patients with Parkinson’s disease with motor fluctuations: experience from a tertiary center
Objective: To assess effectiveness and safety profile of Opicapone in our cohort of patients with Parkinson’s disease (PD) who received this treatment. Background: Opicapone is…Effects of Once-Daily Opicapone 50 mg on COMT activity: A Pooled Post-hoc Analysis of Two Phase 1 Studies
Objective: To assess the effects of opicapone (OPC) 50 mg adjunct to carbidopa/levodopa (CD/LD) on catechol-O-methyltransferase (COMT) activity by participants’ baseline characteristics using pooled data…Safety of opicapone after 5 years of post-marketing experience worldwide
Objective: To review the safety data of opicapone (OPC) after five years of marketing experience worldwide Background: OPC is a once-daily catechol-O-methyltransferase (COMT) inhibitor proven…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 12
- Next Page »